Breaking News

Financial Report: Roche

January 30, 2013

Pharma sales up 2% in the quarter


FY Revenues: $49.8 billion (+1%)

FY Earnings: $10.7 billion (+5%)

Comments: Pharmaceutical Division sales were $38.6 billion, up 2%. MabThera/Rituxan sales were $7.3 billion (+9% in local currencies). Herceptin sales were $6.4 billion (+11% lc). Avastin sales were $6.3 billion (+6% lc). Diagnostics Division revenues were flat at $11.2 million. R&D spend was $8.2 billion, up 2%.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks